Octant essay: AI shifting drug discovery from lab-in-the-loop to agentic workflows
anshulkundaje · x · 2026-09-25
Octant founder Srinivas Kasetti's essay 'Mens et Manus' details how AI is reshaping the company: the team has evolved from lab-in-the-loop applications to more agentic ways of working on frontier drug programs, where you don't even know what question to answer. He opens with a thought experiment: could MIT's 1860s founders, given unmetered intelligence but only period knowledge, have said 'Claude, build a transistor'?
Related event: Octant: AI Agents Are Reshaping Drug Discovery(3 posts)→
More from AGI Musings
- Sam Altman: beating competitors is no reason for rash AI decisions — haider1 · 2026-09-25
- Benchmark's Bill Gurley: Being an AI alarmist isn't a social good — kevinnbass · 2026-09-25
- Developer: today's AI is a primitive form of machine consciousness — "you can laugh now" — ctjlewis · 2026-09-25
- "It's all just matrix multiplications" is the new "love is just chemistry" — aran_nayebi · 2026-09-25
- Larry Page saw it in 2007: AI will be a lot of computation, not clever algorithms — jw2yang4ai · 2026-09-25
- Anthropic: AI agents now do 26% of its internal research, up from under 1% — mtizard · 2026-09-25